Pyoderma gangrenosum - Pijoderma Gangrenosum
Pijoderma Gangrenosum (Pyoderma gangrenosum) hija marda rari u infjammatorja tal-ġilda fejn pustuli jew noduli bl-uġigħ isiru ulċeri li jikbru progressivament. pijoderma gangrenosum (pyoderma gangrenosum) mhuwiex infettiv. It-trattamenti jistgħu jinkludu kortikosterojdi, ciclosporin, jew diversi antikorpi monoklonali. Għalkemm jista 'jaffettwa nies ta' kull età, jaffettwa l-aktar nies fl-40 u l-50 sena.
☆ Fir-riżultati ta' Stiftung Warentest tal-2022 mill-Ġermanja, is-sodisfazzjon tal-konsumatur b'ModelDerm kien biss ftit inqas milli b'konsultazzjonijiet bit-telemediċina mħallsa.
Fuq riġel ta 'persuna b'kolite ulċerattiva.
References
Pyoderma gangrenosum hija kundizzjoni rari tal-ġilda li tikkawża ulċeri bl-uġigħ bi truf ħomor jew vjola. Hija kklassifikata bħala marda infjammatorja u hija parti minn grupp imsejjaħ dermatoses newtrofiliċi. Il-kawża ta ' pyoderma gangrenosum hija kumplessa, li tinvolvi problemi kemm bl-immunità intrinsika kif ukoll bl-immunità adattiva f'nies li huma suxxettibbli ġenetikament. Riċentement, ir-riċerkaturi ffukaw fuq il-follikulu tax-xagħar bħala punt tat-tluq potenzjali tal-marda.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum hija kundizzjoni rari tal-ġilda li tikkawża ulċeri ta' wġigħ kbir. Filwaqt li ma nifhmux bis-sħiħ il-kawża tagħha, nafu li tinvolvi attività akbar ta 'ċerti ċelluli immuni. It-trattament tal-marda għadu mhux faċli. Għandna diversi mediċini li jrażżnu s-sistema immuni jew jimmodifikaw l-attività tagħha. Flimkien ma’ dawn, aħna niffukaw ukoll fuq it-trattament tal-feriti u l-ġestjoni tal-uġigħ. Il-kortikosterojdi u ċ-ċiklosporina ħafna drabi huma l-ewwel għażla għat-trattament, iżda dan l-aħħar, kien hemm aktar riċerka dwar l-użu ta 'terapiji bijoloġiċi bħall-inibituri TNF-α. Dawn il-bijoloġiċi huma dejjem aktar preferuti, speċjalment f'pazjenti b'kundizzjonijiet infjammatorji oħra, u qed jintużaw aktar kmieni fil-proċess tal-marda.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
